A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Neoplasms
Interventions
DRUG

ADH-1

4 gm IV Days 1 and 8

DRUG

melphalan

By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1

Trial Locations (7)

18103

Lehigh Valley Hospital, Allentown

27516

Duke University Medical Center, Durham

32610

University of Florida College of Medicine, Gainesville

33612

H. Lee Moffitt Cancer Center, Tampa

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Denver, Aurora

84157

Intermountain Medical Center, Murray

Sponsors
All Listed Sponsors
lead

Adherex Technologies, Inc.

INDUSTRY

NCT00421811 - A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan | Biotech Hunter | Biotech Hunter